Previous 10 | Next 10 |
Image source: The Motley Fool. Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Q1 2020 Earnings Call May 7, 2020 , 9:00 p.m. ET Operator Continue reading
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2020 Earnings Conference Call May 6, 2020 9:00 A.M. ET Company Participants Peter Vozzo - Managing Director, Westwicke Jack Khattar - President and Chief Executive Officer Gregory Patrick - Chief Financial Officer Conference Call Partic...
Supernus Pharmaceuticals (NASDAQ: SUPN ): Q1 GAAP EPS of $0.40 beats by $0.13 . Revenue of $94.97M (+11.1% Y/Y) beats by $10.96M . Shares +22.7% AH. Press Release More news on: Supernus Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks n...
First quarter total revenue of $95.0 million, an 11% increase over 2019 First quarter net product sales of $92.5 million, an 11% increase over 2019 First quarter operating earnings of $29.0 million, a 14% increase over 2019 On track for launch of SPN-812 at the end of 2020, pending FDA ...
Self-respect is the root of discipline: The sense of dignity grows with the ability to say no to oneself . - Abraham Joshua Heschel The biotech sector continues to hold up very well despite a volatile market. The SPDR Biotech ETF ( XBI ) has recovered all of its COVID-19 meltdown sell-o...
Supernus Pharmaceuticals (NASDAQ: SUPN ) agrees to acquire the central nervous system portfolio of US WorldMeds, a privately held biopharmaceutical company, for $530M. More news on: Supernus Pharmaceuticals, Inc., Healthcare stocks news, Merger & acquisition news, Read more ...
Expands and strengthens neurology portfolio with three marketed CNS products and late-stage pipeline Diversifies revenue and operating cash flow base with 2019 net sales of approximately $150 million and operating earnings of $45 million Enhances long term growth with po ...
ROCKVILLE, Md., April 24, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report busine...
Stocks in the biotech sector have generally held up well during the market sell-off caused by the COVID-19 pandemic. Two of the leading biotechnology exchange-traded funds (ETFs), the iShares Nasdaq Biotechnology ETF and the SPDR S&P Biotech ETF , have quickly rebounded from the...
Companies to Collaborate on Phase II Development for NV-5138 in Depression NV-5138 is a Novel First-in-Class Activator of mTORC1 Supernus Receives Exclusive Option to License or Acquire NV-5138 Prior to Initiation of Phase III Clinical Program ROCKVILLE, Md. and CAMBRIDGE, Mass., Apri...
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial ...
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...